Clovis Oncology (FRA:C6O) Short-Term Capital Lease Obligation : €3.5 Mil (As of Sep. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Clovis Oncology Short-Term Capital Lease Obligation?

Clovis Oncology's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2022 was €3.5 Mil.

Clovis Oncology's quarterly Short-Term Capital Lease Obligation increased from Mar. 2022 (€3.2 Mil) to Jun. 2022 (€3.4 Mil) and increased from Jun. 2022 (€3.4 Mil) to Sep. 2022 (€3.5 Mil).

Clovis Oncology's annual Short-Term Capital Lease Obligation declined from Dec. 2019 (€4.9 Mil) to Dec. 2020 (€4.4 Mil) and declined from Dec. 2020 (€4.4 Mil) to Dec. 2021 (€3.0 Mil).

Clovis Oncology Short-Term Capital Lease Obligation Historical Data

The historical data trend for Clovis Oncology's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clovis Oncology Short-Term Capital Lease Obligation Chart

Clovis Oncology Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.91

4.87

4.38

3.02

Clovis Oncology Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.96	3.02	3.23	3.41	3.49

Clovis Oncology Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Clovis Oncology Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Clovis Oncology's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Clovis Oncology (FRA:C6O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clovis Oncology Inc (FRA:C6O) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301

Website

https://www.clovisoncology.com

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.

Clovis Oncology (FRA:C6O) Headlines

No Headlines